CAS 103060-53-3 Daptomycin Antibacteria Medical Material

Daptomycin 99%

CAS: 103060-53-3

Quality Standard: in house

Apperance: White crystalline power

(Daptomycin) is by Lilly (Lilly) company original research, Cubist pharmaceutical companies develop a ring fat peptide antibiotics.Deal with resistance to new antibiotics the pressing needs of the patient, at the end of 2003, the United States food and drug administration (FDA) following a quick trial program approval for injection of tora toxin (Daptomycin) (trade name cubicin) used to treat some gram positive strains of the sensitive concurrency skin and skin structure infections, such as abscess, infection of incision and skin ulcers.Of different mechanism of the drug, and other antibiotics, it by disrupting the cell membrane transport of amino acids, which hinder the biosynthesis of bacterial cell wall peptidoglycan, change the nature of the cytoplasmic membrane;In addition, it can destroy bacteria cell membrane, make its contents were leaked and reach the purpose of sterilization, because bacteria for drug resistance may be more difficult.

The molecular structure
Of azithromycin is rose spore streptomycete A21978C fat peptide compounds of fermented product by N - decyl acyl derivatives, are fat acid ring peptide antibiotics.Of fosomycin contains 13 amino acids, including 10 ten fat peptide, amino acid to form ring the other

3 and decyl acyl amino acids to form outside side chain, complicated structure, difficult to chemical synthesis.
Of azithromycin is the second generation after vancomycin sugar peptide antibiotics, is extracted from Streptomyces fermentation contained a cyclic ester of peptides, it not only has the novel chemical structure, and its action mode is different from any listed have been allowed to antibiotics, used as an effective alternative to vancomycin, pharmaceutical enterprises in China in recent years for the generic drug product as substantial progress has been made, the sea is pharmaceutical of 5 tons of fosomycin API project is under construction, zhejiang medicine currently has 2 tons/year production capacity.
But the enterprise obtain the SFDA production approval will take time, the current domestic of fosomycin products rely on imports to meet.In China in 2010 up to 56147 bottles of drug supply to/teams, 2012 reached * * bottles/domestic supply.